Groupe Hospitalier Bichat Claude Bernard, AP-HP

Paris 75018

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung

Studies at this site

• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC — Running, not enrolling